We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 29, 2011
Last Update Posted: March 13, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Curis, Inc.
This is a phase I dose escalation study of CUDC-101 in combination with concurrent cisplatin and radiation therapy in patients with locally advanced head and neck cancer. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2 (Her2) and histone deacetylase (HDAC). The study is designed to establish the safety, tolerability and maximum tolerated dose (MTD) of CUDC-101 when administered in combination with concurrent cisplatin and radiation over an 8-week treatment course, consisting of a one week run-in period of CUDC-101 administered alone, followed by seven weeks of combination treatment with CUDC-101, cisplatin and radiation therapy.

Condition Intervention Phase
Head and Neck Cancer Drug: CUDC-101 Drug: Cisplatin Radiation: Radiation Therapy Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer

Resource links provided by NLM:

Further study details as provided by Curis, Inc.:

Primary Outcome Measures:
  • To establish the safety and tolerability of CUDC-101 when administered in combination with concurrent cisplatin and radiation in subjects with locally advanced head and neck cancers. [ Time Frame: 18-24 months ]
    Safety and tolerability will be assessed by the number of participants with adverse events and will determine the maxiumum tolerated dose of CUDC-101 in combination with cisplatin and radiation.

Secondary Outcome Measures:
  • To evaluate the efficacy of CUDC-101, cisplatin and radiation combination therapy. [ Time Frame: 18-24 months ]
    Efficacy of CUDC-101 will be determined by the number of subjects disease free at the completion of the treatment period and the number of subjects remaining disease free in the follow up period.

  • To assess the pharmacokinetics of CUDC-101. [ Time Frame: 18-24 months ]
    Pharmacokinetics will involve a determination of the concentration of CUDC-101 in the blood over time.

  • To evaluate the pharmacodynamic effects of CUDC-101. [ Time Frame: 18-24 months ]
    The ability of CUDC-101 to exert a biological effect on the tumor will be examined in pharmacodynamic samples.

Enrollment: 12
Study Start Date: November 2011
Study Completion Date: October 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: CUDC-101
    CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
    Drug: Cisplatin
    Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
    Other Names:
    • cisplatinum
    • CDDP
    • Platinol
    Radiation: Radiation Therapy
    The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with locally advanced, pathologically confirmed diagnosis of squamous cell carcinoma of the head and neck at the following sites: oral cavity, oropharynx, hypopharynx and larynx with either:

    • Stage IV p16 positive tumors and >10 pack-years smoking history.
    • Stage III/IV p16 negative tumors, regardless of smoking history.
  • At least evaluable disease; one measurable site of disease according to RECIST (Version 1.1) criteria (at least 10 mm for conventional CT/MRI or spiral CT scan) is desirable.
  • Subjects enrolled in the MTD expansion cohort must have at least 1 tumor lesion that is suitable for repeat biopsy (pre- and post-CUDC-101 infusion).
  • Age ≥ 18 years
  • ECOG performance < 2
  • Life expectancy ≥ 3 months
  • If female, neither pregnant nor lactating
  • If of child bearing potential, must use adequate birth control throughout the participation in the treatment phase and for 60 days following the last study treatment.
  • Absolute neutrophil count ≥ 1,800/µL; platelets ≥ 100,000/µL; hemoglobin ≥ 8.0 g/dL, creatinine ≤ 1.5x upper limit of normal (ULN); total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2 x ULN.
  • Serum magnesium and potassium within normal limits (may be supplemented to achieve normal values)
  • Able to render informed consent and to follow protocol requirements.

Exclusion Criteria:

  • Prior radiotherapy to the region of the study cancer or adjacent anatomical sites, or > 25% of marrow-bearing area.
  • Prior chemotherapy for the current indication.
  • Prior therapy that specifically and directly targets EGFR, HER2 or HDAC.
  • Use of investigational agent(s) within 30 days prior to study treatment.
  • Primary tumor site of nasopharynx, sinuses, or salivary gland.
  • History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment.
  • Patients with prolonged QTc Interval >450 msec.
  • Acquired Immune Deficiency Syndrome (AIDS) or known infection with human immunodeficiency virus (HIV). Testing is not required.
  • Known history of gastrointestinal bleeding, ulceration, or perforation within 6 months prior to study treatment.
  • Known history of stroke or cerebrovascular accident within 6 months prior to study treatment.
  • Symptomatic cardiac conduction abnormality within 12 months prior to study treatment.
  • Prior history of hearing impairment.
  • Known history of renal disease or ongoing renal impairment.
  • Any uncontrolled condition (such as active systemic infection, diabetes, hypertension), which in the opinion of the investigator, could affect the subjects participation in the study.
  • Prior allergic reaction to cisplatin, carboplatin or other platinum-containing compounds.
  • Central nervous system metastases.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01384799

United States, California
Stanford Cancer Center
Stanford, California, United States, 94305
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Louisiana
Overton Brooks VA Medical Center
Shreveport, Louisiana, United States, 71101
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 01911
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Curis, Inc.
  More Information

Responsible Party: Curis, Inc.
ClinicalTrials.gov Identifier: NCT01384799     History of Changes
Other Study ID Numbers: CUDC-101-103
First Submitted: June 17, 2011
First Posted: June 29, 2011
Last Update Posted: March 13, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Antineoplastic Agents